HSS Journal

, Volume 2, Issue 1, pp 30–41

Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals

Original Article

DOI: 10.1007/s11420-005-0133-z

Cite this article as:
Gibofsky, A. HSS Jrnl (2006) 2: 30. doi:10.1007/s11420-005-0133-z


Early, aggressive disease management is critical for halting disease progression and joint destruction in patients with rheumatoid arthritis. Combination therapy with at least two disease-modifying antirheumatic drugs, such as methotrexate (MTX), sulfasalazine, or hydroxychloroquine, is often more effective than monotherapy in reducing disease activity. Biologic therapies represent more effective and tolerable treatment options that, when combined with MTX, have been shown to dramatically reduce inflammation, inhibit radiographic progression, and induce remission. Although several types of treatment strategies are used in clinical practice, the most aggressive approaches that target early disease have shown the most promise in reversing disease progression and reducing disease-related costs.

Key words

combination therapydisease-modifying antirheumatic drugsjoint destructionrheumatoid arthritistumor necrosis factor antagonists

Copyright information

© Hospital for Special Surgery 2006

Authors and Affiliations

  1. 1.Departments of Medicine and Public HealthWeill Medical College of Cornell UniversityNew YorkUSA
  2. 2.Hospital for Special SurgeryNew YorkUSA